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INTRODUCTION 
Hyperlipidemia, diabetes mellitus, hypertension are combinable and may lead to development of 
metabolic syndrome
1
. Free radicle formation in human body is normal, but there are chances of 
development of atherosclerotic plaques if these free radicles are interacted with high plasma 
lipids
2
. Atherosclerotic plaques are stuck with endothelial layer of coronary arteries leading to 
development of coronary artery disease (CAD)
3
. Hypertension, CCF, cardiac arrest, and cardiac 
arrhythmia are consequences of CAD
4
. One of the factors causing CAD is abnormal plasma lipid 
levels
5
. For prevention of CAD, either blood lipids must be at normal levels or free radicle 
formation must be reduced
6
. In allopathy niacin, statins, fibrates and psyllium are used as 
hypolipidemic agents. Vitamin C, vitamin E, adenosine, lactoferrin and carotenoids are used as 
antioxidant drugs
7
. Fenofibrate causes activation of peroxisome proliferator activated receptor α 
(PPARα),  leading to increased lipolysis and elimination of triglyceride-rich particles from 
plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor 
of lipoprotein lipase activity)
8
. Nigella sativa or Kalonji is being used as medicinal herb since 
pre-historical times. It contains carvacrol, nigellicine, polyunsaturated fatty acids, alphahederin, 
thymoquinone, mucilage, sterols, and migellamine
9
. Kalonji affects HMG-Co-A reductase 
leading to decreased formation of cholesterol in hepatocytes
10
. This herb contain thymoquinone 
which inhibits lipid peroxidation in liposomes
11
. Alphahederin, thymoquinone, mucilage, sterols, 
and migellamine present in kalonji scavenge  superoxide anion and hydroxyl radicles leading to 
decreased chances of LDL oxidation, and development of coronary artery disease
12
. 
PATIENTS & METHOD 
TYPE OF STUDY: The research work was single blind placebo-controlled, conducted at Ghurki 
trust teaching Hospital, Lahore from February 2017 to July 2017. PATIENTS & CONSENT: 
Seventy five hyperlipidemic patients were selected for research work. Written consent was taken 
from all patients. INCLUSION CRITERIA: 75 diagnosed secondary hyperlipidemic patients 
were selected with age range from 20 to 70 years. EXCLUSION CRITERIA: Exclusion criteria 
were hypothyroidism, diabetes mellitus, alcohol addictive patients, peptic ulcer, any 
gastrointestinal upset, renal impairment, and any hepatic or cardiac problem. GROUPING: All 
patients were divided in three groups (group-A, group-B, group-C), 25 in each group. Their 
baseline experimental data was taken and filed in specifically designed Performa, at start of 
taking medicine, like lipid profile, blood pressure and pulse rate. The study period was eight 
weeks. Twenty five patients of group-A were advised to take two grams of Kalonji, twice daily. 
Twenty five patients of group-B were advised to take Fenofibrate 40 mg tablets, BD ie;  one after 
breakfast and one after dinner. Twenty five patients were provided placebo capsules, (containing 
grinded sorghum), taking one capsule after breakfast and another before going to bed. All 
participants were advised to take these medicines for eight weeks. They were also advised for 20 
minutes brisk walk at morning or evening time. Patients were called every 2 weeks for follow up 
to check blood pressure, weight, pulse rate etc. Drug compliance to the regimen was monitored 
by interview and counseling at each clinical visits. METHOD: Serum LDL-cholesterol was 
calculated by Friedwald formula
13
 (LDL-Cholesterol = Total Cholesterol-(Triglycerides/5 
+HDL-Cholesterol). BIOSTATISTICAL ANALYSIS: Data were expressed as the mean ± SD 
  
 
and “t” test was applied to determine statistical significance as the difference. A probability 
value of <0.05 was considered as non-significancant and P<0.001 was considered as highly 
significant change in the results when pre and post-treatment values were compared.  
RESULTS 
When results were compiled and statistically analyzed by using SPSS, it was observed that 
Nigella sativa and fenofibrate decreased total-cholesterol, LDL-cholesterol, triglycerides highly 
significantly (p-value <0.001) and increased HDL-cholesterol significantly (p-value <0.01) as 
compared to placebo treatment. Results are summarized as:  
Effects of Kalonji on lipid profile of 25 hyperlipidemic patients:  TC at day-0 was 231.21±1.12 
mg/dl which reduced to 200.90±3.11 mg/dl. The overall change in the parameter was 30.31 (P-
value= <0.001). TG at day-0 was 178.90±3.01 mg/dl which reduced to 141.10±1.01 mg/dl. 
Change was 37.80 ( P-value= <0.001). LDL-C at day-0 was 191.14±3.45 mg/dl which reduced to 
159.40±2.98 mg/dl. Change was 31.74 (P-value= <0.01).  HDL-C at day-0 was: 36.48±2.11 
mg/dl which increased to 41.17±1.88 mg/dl. Incraese in the parameter was 4.69 ( p-value = 
<0.01) Effects of GEMFIBROZIL on 25 hyperlipidemic patients: TC at day-0 was 240.92±2.21 
mg/dl which reduced to 197.31±1.00  mg/dl. In mg/dl this change was 43.61  with P-value= 
<0.001. TG at day-0 was 204.31±1.26  mg/dl which reduced to 170.14±2.93 mg/dl. Reduction in 
mg/dl it was 34.17 ( P-value= <0.001). LDL-C at day-0 was 197.77±3.91 mg/dl which reduced 
to 159.62±2.20 mg/dl. Over all change was 38.15 with P-value= <0.001. HDL-C at day-0 was 
32.97±3.10 mg/dl which increased to 40.45±2.22 mg/dl. Increased in mg/dl it was 7.48 mg/l.                                                     
P-value= <0.01. 
Placebo Effects on 25 hyperlipidemic patients: TC at day-0 was 213.11±2.32 mg/dl which 
reduced to 210.10±2.91 mg/dl. P-value= >0.05. TG at day-0 was 170.00±3.01 mg/dl which 
reduced to 161.70±3.91 mg/dl with P-value= >0.05.  LDL-C at day-0 was 163.104±1.45 mg/dl 
which reduced to 159.40±1.77 mg/dl (P-value= >0.05). HDL-C at day-0 was 31.12±1.01 mg/dl 
which increased to 31.69±2.00 mg/dl. P-value= >0.05 
DISCUSSION 
Nigella sativa and Fibrates are very good hypolipidemic agents which can be used alone or in 
combination. Changes in all parameters of 25 hyperlipidemic patients lipid profile (i.e.; serum 
cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol) were highly significant in two 
drug groups when they compared with placebo-controlled group, except change in serum total 
cholesterol in Nigella sativa group, which is significant with probability value  <0.01.  Our 
results regarding lipid lowering effects of Nigella sativa match with results of research work 
conducted by Fiju G et al
14
 match with research study conducted by , who did see reduction of 
serum total cholesterol 13.01 %, triglycerides 9.1 % and 17.89 %. HDL-cholesterol increased 
23.62 %.  Merghatt V et al
15
 proved highly significant changes in lipid parameters of 
hyperlipidemic rats when they used one teaspoon of Nigella sativa oil twice daily for 3 weeks. 
These results match with results of our work. Jimiyath CT et al
16
 conducted research on 
hyperlipidemic patients and proved 12.76, 8 % , 15 % decrese in serum cholesterol, triglycerides, 
and LDL-cholesterol in 19 days when they used kalongi oil. They have explained marked 
protective action of Nigella sativa against ischemic reperfusion-induced gastric mucosal lesions, 
an effect that was mediated by suppression in the level of lipid peroxide and lactic 
dehydrogenase and an increase in those in glutathione and superoxide dismutase. The results of 
research work conducted by Rolkerr F
17
 do not match with our results who observed 10.11 %, 
12.51 %, 12.45 % reduction in total cholesterol, triglycerides, and LDL-cholesterol when they 
used kalongi oil for two months in hyperlipidemic patients. This difference in results may be due 
  
 
to large difference in sample size of tested group individuals. Turnorj F et al
18
 observed much 
higher quantity of reduction in LDL-Cholesterol (-30.11 %) when they used two spoons of 
Nigella sativa in 1000 hyperlipidemic patients for the period of 6 months. This difference is 
surely due to large sample size in their study and duration of research study. Our results are in 
contrast with research work results of  Erovha E et al
19
 who observed(11 %) increase in HDL-
cholesterol with use of Kalonji for 4 weeks in 19 patients suffering from hyperlipidemia. Qulath 
C et al
20
 describes more than six mechanism by which Kalonji affects blood lipids, Enterohepatic 
circulation inhibition is one of them. Askalth VV et al
21
 have emphasized not to combine seeds 
of kalonji with vitamin D and E, as absorption of these vitamins may be decreased leading to 
iatrogenic effects like SUPERINFECTIONS. Parjhat K et al
22
, and Soghan MM et al
23
 observed 
same effects of Kalonji as ours. Results of study by Rullt FD et al
24
, and Wksort VB et al
25
 
support our results.  In our results  Fenofibrate decreased TC 43.61 mg/dl, TG 34.17 mg/dl, 
LDL-C 38.15 mg/dl, and increased HDL-C 7.48 mg/dl. Same response was observed by 
Qulchawt C et al25, and Dadhagirr CD et al26. However Erjhoth T et al27 and Polandf YT et 
al28 proved that fenofibrate do not increase HDL-C in hyperlipidemic patients unless given in 
high doses ie; more than 200 mg per day for considerable time.  
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